Lifileucel (lifileucel)
Iovance Biotherapeutics · Tumor-Infiltrating Lymphocyte (TIL) Therapy
What is Lifileucel? Lifileucel (brand: Amtagvi) is the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy, approved for adult patients with unresectable or metastatic melanoma who have received prior treatment with a PD-1/PD-L1 blocking antibody and a BRAF inhibitor (if BRAF V600 mutation positive).
About Lifileucel
| Brand Name | Lifileucel |
| Generic / INN | lifileucel |
| Drug Class | Tumor-Infiltrating Lymphocyte (TIL) Therapy |
| Manufacturer | Iovance Biotherapeutics |
| Administration | IV infusion (autologous, patient-specific) |
| FDA Approval | 2024 |
FDA-Approved Uses for Lifileucel
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Unresectable or metastatic melanoma — adult patients after prior treatment with a PD-1/PD-L1 checkpoint inhibitor and a BRAF inhibitor (if BRAF V600 mutation-positive)
How Does Lifileucel Work?
Lifileucel consists of tumor-infiltrating lymphocytes (TILs) — immune cells naturally present within the patient's own tumor. TILs are harvested from a resected tumor fragment, expanded ex vivo to large numbers (up to billions of cells), and infused back into the patient after lymphodepleting chemotherapy. The expanded TILs have diverse natural T-cell receptors recognizing tumor-specific antigens and attack melanoma cells without genetic engineering.
Dosage & Administration
Single IV infusion following non-myeloablative lymphodepleting chemotherapy (fludarabine + cyclophosphamide), then high-dose interleukin-2 (aldesleukin) after infusion. The number of cells infused is patient-specific (minimum 7.5 × 10⁹ viable cells). The full process takes approximately 5–7 weeks from tumor harvest to infusion.
Warnings, Precautions & Side Effects
General Warning
Cytokine release syndrome (CRS). Prolonged severe cytopenias. Severe infections. Prolonged immune deficiency. Respiratory failure. High-dose IL-2 toxicity (required post-infusion): capillary leak syndrome, hypotension, pulmonary edema. Neurological toxicity. Available only at certified healthcare facilities.
Common Side Effects
- CRS
- Prolonged cytopenias
- Infections
- Nausea
- Fatigue
- IL-2 toxicity effects
- Hypotension
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Cryopreserved product — stored in liquid nitrogen vapor phase (≤ −130°C). Must be shipped and handled under validated cryogenic conditions.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Lifileucel is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Lifileucel. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Lifileucel
Lifileucel (Amtagvi) is the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy, approved in 2024 for unresectable or metastatic melanoma after prior checkpoint inhibitor therapy (and BRAF inhibitor if BRAF-mutated).
CAR-T cells are genetically engineered to express a specific synthetic receptor targeting one antigen. TIL therapy uses the patient's own naturally occurring tumor-reactive T cells — harvested from the tumor itself — which have diverse natural T-cell receptors and can recognize multiple tumor antigens simultaneously.
High-dose interleukin-2 (IL-2/aldesleukin) is given after the TIL infusion to expand and sustain the infused lymphocytes. IL-2 causes significant toxicities (capillary leak, hypotension) that require intensive monitoring at certified facilities.
As a 2024 FDA approval, coverage is still being established across plans. Prior authorization with full documentation of prior therapy (checkpoint inhibitor + BRAF inhibitor if applicable) is required. BiologicHealthPlus assists with access coordination.
Related Medications & Conditions
Related Medications
Keytruda (pembrolizumab) · Opdivo (nivolumab) · Tafinlar + Mekinist (BRAF/MEK) · Yescarta · Abecma
Related Conditions
Unresectable melanoma · Metastatic melanoma · Advanced skin cancer